Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2025-10-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 448.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Q1 ACTIVITIES REPORT 30 SEPTEMBER 2025' and contains detailed financial and operational information for the quarter ending September 30, 2025. It includes revenue figures, cash flow statements, operational highlights, regulatory updates, and outlook commentary. The presence of an Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, further confirms this is a quarterly financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes actual financial data and analysis for the quarter, not just a summary or announcement of a report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2025-10-29 English
Presentation on FY2025 Quarter 1 Results 11 pages 742.8KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation on the first quarter results for FY2025 by Bioxyne Limited. It includes financial highlights such as revenue growth, cash flow details, and outlook for the fiscal year. The text explicitly mentions it is a "Presentation on FY25 Q1 Results" and contains forward-looking statements, financial data, and operational updates. It is not a full annual or interim report but a presentation summarizing quarterly financial results and business outlook. Therefore, it fits the category of an Investor Presentation (IP) rather than an Interim Report (IR) because it is styled as a presentation and includes strategic and operational commentary alongside financials. The document length (15,000 characters) and content confirm it is not a brief announcement or a regulatory filing. Hence, the classification is Investor Presentation (IP) with high confidence.
2025-10-29 English
Application for quotation of securities - BXN 7 pages 20.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and related information. This type of document is a formal announcement related to new securities being quoted on the exchange, which corresponds to a share issue or capital change event. It is not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2025-10-26 English
Change of Director Interest Notice X 2 4 pages 235.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including the number of shares and performance rights acquired or disposed of, nature of interests, and dates of changes. This type of document is a formal notification of personal share transactions by company directors. It is not a financial report, earnings release, or management discussion. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and detail confirm it is the actual notice, not just an announcement or certification. Therefore, the correct classification is DIRS.
2025-10-26 English
Notice of Annual General Meeting/Proxy Form 52 pages 917.0KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING Explanatory Memorandum and Proxy Form' for Bioxyne Limited, with a scheduled meeting date of 26 November 2025. It includes detailed information about the AGM such as resolutions to be voted on, including the remuneration report, re-election of directors, approval of share issues, and ratification of placements. The document contains proxy forms and explanatory statements to assist shareholders in voting. It is a notice and explanatory memorandum for the AGM, not the actual annual report or financial statements. The content aligns with materials typically provided to shareholders ahead of an AGM to inform them and solicit votes. Therefore, this document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed agenda confirm it is not a brief announcement or proxy solicitation only, but the full AGM notice and explanatory memorandum.
2025-10-26 English
Letter to Shareholders re Annual General Meeting 2 pages 277.3KB
AGM Information Classification · 95% confidence The document is titled 'ANNUAL GENERAL MEETING NOTICE AND PROXY FORM' and is dated 27 October 2025. It provides details about the upcoming Annual General Meeting (AGM) of Bioxyne Limited, including the date, time, location, proxy submission instructions, and shareholder voting procedures. It also includes information about the company and its subsidiary but does not contain any financial statements, management discussion, or detailed financial data. The document is relatively short (4792 characters) and serves as a notice and proxy form for the AGM rather than the actual AGM materials or presentations. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and proxy forms.
2025-10-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.